Hepatitis C transmission from seropositive, nonviremic donors to non–hepatitis C liver transplant recipients

Hepatology

Volumn 67, Issue 5, 2018, Pages 1673-1682

  Bari, Khurram ^a   Luckett, Keith ^b   Kaiser, Tiffany ^a   Diwan, Tayyab ^a   Cuffy, Madison ^a   Schoech, Michael R ^a   Safdar, Kamran ^a   Blackard, Jason T ^a   Apewokin, Senu ^b   Paterno, Flavio ^a   Sherman, Kenneth E ^a   Zucker, Stephen D ^a,c   Anwar, Nadeem ^a   Shah, Shimul A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DACLATASVIR; LEDIPASVIR PLUS SOFOSBUVIR; MYCOPHENOLATE MOFETIL; RIBAVIRIN; SOFOSBUVIR; SOFOSBUVIR PLUS VELPATASVIR; TACROLIMUS; ANTIVIRUS AGENT;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL OUTCOME; DISEASE TRANSMISSION; DRUG OVERDOSE; DRUG WITHDRAWAL; FATTY LIVER; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG INFECTION; MALE; MIDDLE AGED; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; ORGAN DONOR; PNEUMONIA; POLYMERASE CHAIN REACTION; PORTOPULMONARY HYPERTENSION; POSTOPERATIVE PERIOD; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA; ADOLESCENT; DONOR; HEPACIVIRUS; INCIDENCE; LIVER; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRANSMISSION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS; YOUNG ADULT;

EID: 85044481987     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29704     Document Type: Article

References (40)

1. Organ Procurement and Transplantation Network. National Data. https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/#. Accessed July 2017.
2. Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, et al. The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant 2017;17:2790-2802.
3. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
4. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
5. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.
6. Busch MP, Tobler LH, Tegtmeier G, Polito A, Quan S, Hirschler NV, et al. Use of third-generation hepatitis C virus (HCV) enzyme immunoassay (EIA) to resolve second-generation HCV EIA-reactive and second-generation recombinant immunoblot assay-indeterminate blood samples: data to support current Food and Drug Administration guidance on HCV lookback. Transfusion 2000;40:10-14.
7. Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C; Hepatitis Group. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8:87-95.
8. Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007;297:724-732.
9. Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L. Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: time for change. Am J Transplant 2017;17:2863-2868.
10. Suryaprasad A, Basavaraju SV, Hocevar SN, Theodoropoulos N, Zuckerman RA, Hayden T, et al. Transmission of hepatitis C virus from organ donors despite nucleic acid test screening. Am J Transplant 2015;15:1827-1835.
11. Hidaka M, Takatsuki M, Soyama A, Miyaaki H, Ichikawa T, Nakao K, et al. Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report. J Med Case Rep 2011;5:276.
12. Takeichi T, Asonuma K, Yamamoto H, Ohya Y, Okumura K, Lee KJ, et al. Liver transplant from an ABO-incompatible and hepatitis C antibody–positive but an HCV-RNA negative living donor in a familial amyloid polyneuropathy patient. Exp Clin Transplant 2013;11:182-185.
13. Kucirka LM, Sarathy H, Govindan P, Wolf JH, Ellison TA, Hart LJ, et al. Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis. Am J Transplant 2011;11:1188-1200.
14. Organ Procurement and Transplantation Network. Understanding the risk of transmission of HIV, hepatitis B, and hepatitis C from U.S. PHS increased risk donors. https://optn.transplant.hrsa.gov/media/2270/dtac_guidance_risks_201706.pdf. Accessed October 2017.
15. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009;49:665-675.
16. Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004;189:7-14.
17. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, Michalak TI. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004;78:5867-5874.
18. COBAS AmpliScreen HCV test, v2.0. Summary of basis for approval. 2002. https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM173203.pdf. Accessed July 2017.
19. COBAS TaqScreen MPX test, version 2.0. 2009. https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM427750.pdf. Accessed July 2017.
20. Procleix Ultrio Assay [package insert]. San Diego, CA: Gen-Probe. 2012. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm335285.pdf. Accessed August 2017.
21. Dryer PD, Limketkai BN, Martin CM, Ma G, Sherman KE, Taylor LE, et al. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women. J Antimicrob Chemother 2009;64:945-948.
22. Blackard JT, Ma G, Limketkai BN, Welge JA, Dryer PD, Martin CM, et al. Variability of the polymerase gene (NS5B) in hepatitis C virus–infected women. J Clin Microbiol 2010;48:4256-4259.
23. Organ Procurement and Transplantation Network. Policy 15: identification of transmissible diseases. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_15. Accessed July 2017.
24. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951-958.
25. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006;43:1277-1283.
26. McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688-693.
27. Melon S, Galarraga MC, Villar M, Laures A, Boga JA, de Ona M, et al. Hepatitis C virus reactivation in anti-hepatitic C virus–positive renal transplant recipients. Transplant Proc 2005;37:2083-2085.
28. Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 2004;16:204-205.
29. Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol 2008;80:1720-1722.
30. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-340.
31. Whitcomb E, Choi WT, Jerome KR, Cook L, Landis C, Ahn J, et al. Biopsies from allograft liver contain histologic features of hepatitis C virus infection following virus eradication. Clin Gastroenterol Hepatol 2017;15:1279-1285.
32. Elmasry S, Wadhwa S, Bang BR, Cook L, Chopra S, Kanel G, et al. Detection of occult hepatitis C virus infection in patients who achieved a sustained virologic response to direct-acting antiviral agents for recurrent infection after liver transplantation. Gastroenterology 2017;152:550-553.
33. Organ Procurement and Transplantation Network. Policy 2: deceased donor organ procurement. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf#nameddest=Policy_02. Accessed July 2017.
34. Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation. Hepatology 2015;61:285-291.
35. Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health 2013;103:e44-e52.
36. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
37. Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, et al. Safety and efficacy of current DAA regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study. Hepatology 2017;66:1090-1101.
38. Theodoropoulos N, Whitson BA, Martin SI, Pouch S, Pope-Harman A. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient. Transpl Infect Dis 2017;19. doi:10.1111/tid.12659.
39. Shah AP, Cameron A, Singh P, Frank AM, Fenkel JM. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens. Transpl Infect Dis 2017;19. doi:10.1111/tid.12660.
40. Levitsky J, Verna EC, O'Leary JG, Bzowej NH, Moonka DK, Hyland RH, et al. Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients. N Engl J Med 2016;375:2106-2108.